tirzepatide heart racing New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report Tirzepatide cuts heart failure risk

Factors affecting injection duration include the underlying cause of deficiency, pregnancy, inflammatory conditions, and medications such as metformin and proton pump inhibitors

The slow titration ladder exists precisely to keep them tolerable

Many more GLP-1 drugs are in development

The goal should not only be losing weight quickly, but building a healthier lifestyle that remains realistic and maintainable over time

The protocol was approved by the Central Adelaide Local Health Network Human Research Ethics Committee (reference number: 2021/HRE00130), and prospectively registered in the Australian New Zealand Clinical Trials Registry (ACTRN12621000878875)

Basal insulin doses were standardised before initiation of tirzepatide or insulin lispro, and insulin titration was then monitored to ensure suitable doses of both insulin glargine and insulin lispro were used, as shown by the levels of glycaemic control achieved